Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 – 11, 2026 March 4, 2026
Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026 February 24, 2026
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults February 20, 2026
UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) ; OLANZAPINE LAI: EU Submission Expected in Q2 2026 January 28, 2026
Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025) December 9, 2025 December 9, 2025
